Endomag secures Cambridge Science Park space for new UK headquarters
Date of Article
Nov 10 2021
Sector
Commercial

Keep Informed

Sign up to our newsletter to receive further information and news tailored to you.

Sign up now
@
GET IN TOUCH
@ Sebastian Denby
Sebastian Denby
Associate
01223 346640 email me about Sebastian
PREV:
NEXT:

Sebastian is a surveyor and is based in our Cambridge office at One Station Square.

I can provide advice on:

Endomag, a breast cancer surgical guidance company and one of the UK’s fastest-growing private technology businesses, has secured 20,386 sq ft of space at 330 Cambridge Science Park. Advised by Carter Jonas, Endomag has agreed a ten-year lease at the world-renowned Science Park location.

Endomag is a global technology company that creates products for use in breast cancer surgery to ensure better outcomes for patients around the world. Many of the world’s leading physicians and hospitals now use the company’s technologies. These are made up of the Sentimag® localisation platform, a small magnetic seed marker called Magseed® and the Magtrace® lymphatic tracer, all of which are used to precisely guide removal of cancerous tissue. 

With the company set to launch a series of new ground-breaking products in 2022, Endomag is relocating from its current UK headquarters at Jeffrey's Building at St John’s Innovation Park to occupy the ground floor and part of the first floor of 330 Cambridge Science Park. 

Sebastian Denby, Commercial, Carter Jonas said: “The Endomag team are leaders in their field, developing technologies that have helped to create completely new surgical techniques and transform cancer care. Their new space must support their ambitions as they rapidly scale up their operations and drive innovation, and it has been great to work with the team in their search for the best location. Cambridge is one of the world’s leading technology hotspots and Cambridge Science Park continues to play a pivotal role in bringing together and supporting the region’s brightest and best talent. It is an ideal place for Endomag to be based and progress their cutting-edge technologies.”

Dr Eric Mayes, CEO, Endomag said: “With the rapid growth in scale, personnel and ambition of Endomag, it became clear that we needed a new, larger working space to enable our highly skilled team to continue developing world-leading products that support patients undergoing breast cancer treatment. This move to the Cambridge Science Park provides us with significant logistical benefits, close ties to a flourishing technology community and allows us to retain our roots in Cambridge. We’re extremely pleased with the plans for our new office and the support from Carter Jonas throughout this process.”

Carter Jonas advised Endomag. Trinity College was advised by Bidwells.